

JCode	Name	Description	Formulary Alternatives
J0129	Abatacept-Orencia	Disease-modifying antirheumatic drug (DMARD)	Inflectra (infliximab-dyyb)
J0178	Aflibercept (Eylea)	Vascular endothelial growth factor (VEGF)	Bevacizumab (Avastin)
J9022	Atezolizumab (Tecentriq)	Antineoplastic/Monoclonal Antibody	None; Part B Drug Criteria for approval
J9047	Carfilzomib (Kyprolis)	Antineoplastic	None; Part B Drug Criteria for approval
J9145	Daratumumab (Darzalex)	Antineoplastic/Monoclonal Antibody	None; Part B Drug Criteria for approval
J9144	Daratumumab, Hyaluronidase-fihj (Darzalex Faspro)	Antineoplastic/Monoclonal Antibody	None; Part B Drug Criteria for approval
J0885	Epoetin alpha (non-ESRD) (Epogen, Procrit, Retacrit)	Erythropoiesis-stimulating agent (ESA)	None; Part B Drug Criteria for approval
J1439	Ferric caboxymaltose (Injectafer)N	Iron for infusion	Ferrlecit (Sodium ferric gluconate), Infed (Iron dextran) and Venofer (Iron Sucrose)
J1442	Filgrastim (Neupogen)	Granulocyte Colony-Stimulating Factor (G-CSF)	Zarxio (filgrastim-sndz)
J1602	Golimumab-Simponi	Disease-modifying antirheumatic drug (DMARD) TNF Antagonist	Inflectra (infliximab-dyyb)
J2323	Natalizumab (Tysabri)	Monoclonal antibody/Gastrointestinal Agent	Inflectra (infliximab-dyyb)
J9299	Nivolumab (Opdivo)	Antineoplastic/Monoclonal Antibody	None; Part B Drug Criteria for approval
J2326	Nusinersen (Spinraza)	Orphan disease drug (SMA)	None; Part B Drug Criteria for approval
J9264	Paclitaxel (Abraxane) Protein Bound	Antineoplastic	None; Part B Drug Criteria for approval
J9271	Pembrolizumab (Keytruda)	Antineoplastic/Monoclonal Antibody	None; Part B Drug Criteria for approval
J9306	Pertuzumab (Perjeta)	Antineoplastic/Monoclonal Antibody	None; Part B Drug Criteria for approval
J9312	Rituximab (Rituxan)	Disease-modifying antirheumatic drug (DMARD)	None; Part B Drug Criteria for approval
J9311	Rituximab and Hyaluronidase (Rituxan Hycela)	Disease-modifying antirheumatic drug (DMARD)	None; Part B Drug Criteria for approval
J3245	Tildrakizumab (Ilumya)	Antipsoriatic	Inflectra (infliximab-dyyb)
J3262	Tocilizumab-(Actemra)	Disease-modifying antirheumatic drug (DMARD)	Inflectra (infliximab-dyyb)
J9355	Trastuzumab (Herceptin)	Antineoplastic/Monoclonal Antibody	None; Part B Drug Criteria for approval
Q5112	Trastuzumab-dttb (Ontruzant)	Antineoplastic/Monoclonal Antibody	None; Part B Drug Criteria for approval

J0586	Abobotulinumtoxin A (Dysport)	Botulinum toxin	BOTOX (Onabotulinumtoxin A), Xeomin (incobotulinumtoxinA)
J0179	Brolucizumab-dbl (Beovu)	Vascular endothelial growth factor (VEGF)	Bevacizumab (Avastin)
J0717	Certolizumab-Cimzia	Disease-modifying antirheumatic drug (DMARD) TNF Antagonist	Inflectra (infliximab-dyyb)
J9173	Durvalumab (Imfinzi)	Antineoplastic/Monoclonal Antibody	None; Part B Drug Criteria for approval
Q4081	Epoetin Alfa esrd on dialysis Epogen	Erythropoiesis-stimulating agent (ESA)	None; Part B Drug Criteria for approval
J1437	Ferric derisomaltose (Monoferic)N	Iron for infusion	Ferlecit (Sodium ferric gluconate), Infed (Iron dextran) and Venofer (Iron Sucrose)
J1554	IM/IV/SQ Ig (Asceniv)	Immune globulin for injection	Octagam and Privigen
J1556	IM/IV/SQ Ig (Bivigam)	Immune globulin for injection	Octagam and Privigen
J1555	IM/IV/SQ Ig (Cuvitru)	Immune globulin for injection	Hizentra, Xembify
J1572	IM/IV/SQ Ig (Flebogamma)	Immune globulin for injection	Octagam, Privigen
J1575	IM/IV/SQ Ig (Hyqvia)	Immune globulin for injection	Hizentra, Xembify
J2778	Ranibizumab-Lucentis	Vascular endothelial growth factor (VEGF)	Bevacizumab (Avastin)
J0587	Rimabotulinumtoxin B (Myobloc)	Botulinum toxin	BOTOX (Onabotulinumtoxin A), Xeomin (incobotulinumtoxinA)
J3111	Romozosumab-aqqg (Evenity)	Monoclonal antibody	Prolia (denosumab), Zoledronic acid
J2820	Sargromastim (Leukine)	Granulocyte Colony-Stimulating Factor (G-CSF)	Zarxio (filgrastim-sndz)
J1447	Tbo-filgrastim (Granix)	Granulocyte Colony-Stimulating Factor (G-CSF)	Zarxio (filgrastim-sndz)
J9999	Unclassified antineoplastic drugs	Unclassified / Unspecified code	None; Part B Drug Criteria for approval
J3590	Unclassified biologics	Unclassified / Unspecified code	None; Part B Drug Criteria for approval
J7799	Unclassified drug, compounded	Unclassified / Unspecified code	None; Part B Drug Criteria for approval
J7999	Unclassified drug, compounded	Unclassified / Unspecified code	None; Part B Drug Criteria for approval
J3490	Unclassified drugs	Unclassified / Unspecified code	None; Part B Drug Criteria for approval
J7699	Unclassified drugs, inhalation solution	Unclassified / Unspecified code	None; Part B Drug Criteria for approval
J8999	Unspecified oral drug, chemotherapeutic	Unclassified / Unspecified code	None; Part B Drug Criteria for approval
J8499	Unspecified oral drug, non-chemotherapeutic	Unclassified / Unspecified code	None; Part B Drug Criteria for approval

J3357	Ustekinumab-Stelara	Disease-modifying antirheumatic drug (DMARD)	Inflectra (infliximab-dyyb)
J0177	Aflibercept HD (Eylea HD)	Vascular endothelial growth factor (VEGF)	Bevacizumab (Avastin)
J9061	Amivantamab-VMJW (Rybrevant)	Anti-Neoplastic agents (Oncology)	None; Part B Drug Criteria for approval
J0485	Belatacept Injection (Nulojix)	Immunosuppresant	None; Part B Drug Criteria for approval
J9042	Brentuximab Vedotin (Adcetris)	Anti-Neoplastic agents (Oncology)	None; Part B Drug Criteria for approval
J3392	Casgevy	Gene Therapy	None; Part B Drug Criteria for approval
J9119	Cemiplimab-RWLC (Libtayo)	Anti-Neoplastic agents (Oncology)	None; Part B Drug Criteria for approval
J9272	Dostarlimab-GXLY (Jemperli)	Anti-Neoplastic agents (Oncology)	None; Part B Drug Criteria for approval
J9177	Enfortumab Vedotin-EJFV (Padcev)	Anti-Neoplastic agents (Oncology)	None; Part B Drug Criteria for approval
J2777	Faricimab-SVOA (Vabysmo)	Vascular endothelial growth factor (VEGF)	Bevacizumab (Avastin)
J1786	Imiglucerase (Cerezyme)	Enzyme, Enzyme replacement	Infliximab-dyyb (Inflectra), Infliximab-abda (Renflexis), Infliximab-axxq (Avsola)
J1561	Immune Globulin Non-Lyophilized (Gamunex, Gammaked)	Immunoglobulins (IVIG)	Infliximab-dyyb (Inflectra), Infliximab-abda (Renflexis), Infliximab-axxq (Avsola)
J1745	Infliximab (Remicade)	Anti-Rheumatoid, Inflammatory Bowel Disease (IBD) Biologics	None; Part B Drug Criteria for approval
J9228	Ipilimumab (Yervoy)	Anti-Neoplastic agents (Oncology)	None; Part B Drug Criteria for approval
J0896	Luspatercept-AAMT (Reblozyl)	Blood clotting/Coagulation factors (Anti-Hemophilia)	None; Part B Drug Criteria for approval
J3394	Lyfgenia	Gene Therapy	None; Part B Drug Criteria for approval
J2350	Ocrelizumab (Ocrevus)	Multiple Sclerosis agents	None; Part B Drug Criteria for approval
J9316	Pertuzumab, Trastuzumab, Hyaluronidase-ZZXF (Phesgo)	Anti-Neoplastic agents (Oncology)	None; Part B Drug Criteria for approval
J9380	Teclistamab-CQYV (Tecvayli)	Anti-Neoplastic agents (Oncology)	None; Part B Drug Criteria for approval
J9347	Tremelimumab-ACTL(Imjudo)	Anti-Neoplastic agents (Oncology)	None; Part B Drug Criteria for approval
J3380	Vedolizumab (Entyvio)	Anti-Rheumatoid, Inflammatory Bowel Disease (IBD) Biologics	None; Part B Drug Criteria for approval
J3393	Zynteglo	Gene Therapy	None; Part B Drug Criteria for approval